



Zeal & Innovation in **M**edicine

Ref No.: ZLL/CS/BSE/NSE

Date: 28.06.2023

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we wish to inform you that the Board of Directors in their meeting held on 27th June, 2023 have considered and inter alia approved the following:

- a. Investment of AUD 9,900 (Australian Dollars) in an Australian Company namely ZIMTAS Pty Ltd.
- b. Incorporation of a Subsidiary in UAE by one of the wholly owned subsidiaries of the Company.

The details required under Regulation 30 of SEBI LODR read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is also enclosed as Annexure I & II.

Kindly take the intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015:

Annexure I

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIMTAS PTY LTD The Company was incorporated in December, 2022. Turnover: NIL (As the Company is yet to commence the operations)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	Not a related party transaction and no Promoter/Promoter Group/Group Companies have any interest in the entity being acquired.
3	Industry to which the entity being acquired belongs	Pharmaceuticals
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Acquisition is with an objective of Business Development in Australian and New Zealand markets.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Nature of consideration – whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at	Company will invest AUD 9900

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

	which the shares are acquired	(Australian Dollars) for acquisition of 99% of the Share Capital of ZIMTAS Pty Ltd.
9	Percentage of shareholding /control acquired and / or number of shares acquired	99% of the paid-up share capital of ZIMTAS Pty Ltd.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable as the Company was incorporated in December, 2022.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960



Zeal & Innovation in **M**edicine

Annexure II

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc	<p>i) Entity Name and brief details: ZIM International DMCC or any other name as approved by the regulatory authority (Step-down Subsidiary) will be incorporated as a Subsidiary by ZIM Laboratories, FZE i.e. the proposed company to be incorporated would be a Step-down Subsidiary of ZIM Laboratories Limited.</p> <p>ii) Turnover: NIL (yet to commence business operations)</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not a related party transaction and no Promoter/Promoter Group/Group Companies have any interest in the entity being acquired.
3	Industry to which the entity being acquired belongs	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Incorporation of the Step-down Subsidiary is with an objective of Business Development in MENA and other regions.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

7	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
8	Cost of acquisition or the price at which the shares are acquired	ZIM Laboratories FZE would invest AED 70,000 in Step-down Subsidiary
9	Percentage of shareholding / control acquired and / or number of shares acquired	70% of the paid-up share capital of Step-down Subsidiary
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable as the Company is yet to be Incorporated.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960